A Phase 1 interventional study of Apixaban in Healthy Volunteers, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-08-22.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the oral bioavailability of Apixaban solution formulation (Treatment B, 10 mg as 25 mL x 0.4 mg/mL) relative to Apixaban tablets (Treatment A, 10 mg as 2 x 5 mg tablets) in healthy subjects.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Apixaban Film coated Tablet Single dose 10 mg orally
Drug: Apixaban
Apixaban Solution Single dose 10 mg orally
Drug: Apixaban
Also known as: BMS - 562247
Adjusted Geometric Mean of the Maximum Observed Plasma Concentration (Cmax) of Apixaban
Serial blood samples for pharmacokinetic analysis were collected at selected times up to 72 hours after each dose. Maximum observed plasma concentration (Cmax) is measured in nanograms per milliliter (ng/mL)
Time frame: Pre-dose and 0.25, 0.50, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, 72 hours post-dose per intervention
Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero Extrapolated to Infinite Time AUC(INF) of Apixaban
Serial blood samples for pharmacokinetic analysis were collected at selected times up to 72 hours after each dose. AUC(INF) is measured in nanogram hours per milliliter (ng\*h/mL)
Time frame: Pre-dose and 0.25, 0.50, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, 72 hours post-dose per intervention
Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-T)] of Apixaban
Serial blood samples for pharmacokinetic analysis were collected at selected times up to 72 hours after each dose. AUC(0-T) is measured in nanogram hours per milliliter (ng\*h/mL)
Time frame: Pre-dose and 0.25, 0.50, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, 72 hours post-dose per intervention
Number of Participants With Serious Adverse Events (SAEs), Treatment-Related Adverse Events (AEs), Deaths or Discontinuation of Study Drug Due to AEs
AE=any new unfavorable symptom, sign or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity or drug dependency/abuse; is life-threatening, an important medical event or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible or missing relationship to study drug. Death=during the study and up to 28 days past study discontinuation. The select AEs were determined using the Medical Dictionary for Regulatory Activities (MedDRA, v13).
Time frame: Day 1 to 30 days after last dose of study drug
Number of Participants With Marked Laboratory Abnormalities
Clinical laboratory tests were performed pre-study and at selected times throughout the study. Marked laboratory abnormalities were defined as laboratory assessments meeting the following investigator-specified criteria: Leukocytes \< 0.9\* lower limits of normal (LLN), absolute neutrophils + bands \<= 1.500 10\*3 cells/microliter, white blood cells (WBC) urine value \>= 2+. These laboratory abnormalities were not considered clinically significant and therefore not adverse events.
Time frame: Pre-study screen (Day -1) to Day 8 or day of study discharge
| Milestone | Treatment A, Then Treatment B | Treatment B, Then Treatment A |
|---|---|---|
| Started | 7 | 7 |
| Completed | 6 | 7 |
| Not completed | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 |
Serial blood samples for pharmacokinetic analysis were collected at selected times up to 72 hours after each dose. Maximum observed plasma concentration (Cmax) is measured in nanograms per milliliter (ng/mL)
| ng/mL | Treatment A: Apixaban Tablet | Treatment B: Apixaban Oral Solution |
|---|---|---|
| Adjusted Geometric Mean of the Maximum Observed Plasma Concentration (Cmax) of Apixaban | 293.994 (245.998 to 351.354) | 287.164 (242.331 to 340.291) |
Serial blood samples for pharmacokinetic analysis were collected at selected times up to 72 hours after each dose. AUC(INF) is measured in nanogram hours per milliliter (ng\*h/mL)
| ng*h/mL | Treatment A: Apixaban Tablet | Treatment B: Apixaban Oral Solution |
|---|---|---|
| Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero Extrapolated to Infinite Time AUC(INF) of Apixaban | 2712.477 (2414.339 to 3047.432) | 2848.968 (2557.946 to 3173.101) |
Serial blood samples for pharmacokinetic analysis were collected at selected times up to 72 hours after each dose. AUC(0-T) is measured in nanogram hours per milliliter (ng\*h/mL)
| ng*h/mL | Treatment A: Apixaban Tablet | Treatment B: Apixaban Oral Solution |
|---|---|---|
| Adjusted Geometric Mean of the Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-T)] of Apixaban | 2668.310 (2372.198 to 3001.385) | 2784.366 (2497.506 to 3104.175) |
AE=any new unfavorable symptom, sign or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity or drug dependency/abuse; is life-threatening, an important medical event or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible or missing relationship to study drug. Death=during the study and up to 28 days past study discontinuation. The select AEs were determined using the Medical Dictionary for Regulatory Activities (MedDRA, v13).
| participants | Arm A: Apixaban Tablet | Arm B: Apixaban Oral Solution |
|---|---|---|
| SAE | 0 | 0 |
| Treatment-Related AE | 0 | 1 |
| Deaths | 0 | 0 |
| Treatment-Related Deaths | 0 | 0 |
| Discontinuation of Study Drug Due to AEs | 1 | 0 |
Clinical laboratory tests were performed pre-study and at selected times throughout the study. Marked laboratory abnormalities were defined as laboratory assessments meeting the following investigator-specified criteria: Leukocytes \< 0.9\* lower limits of normal (LLN), absolute neutrophils + bands \<= 1.500 10\*3 cells/microliter, white blood cells (WBC) urine value \>= 2+. These laboratory abnormalities were not considered clinically significant and therefore not adverse events.
| participants | Arm A: Apixaban Tablet | Arm B: Apixaban Oral Solution |
|---|---|---|
| Leukocytes, Low | 1 | 1 |
| Absolute Neutrophils + Bands, Low | 1 | 1 |
| WBC, Urine, High | 0 | 1 |
Collected over From first dose to last dose plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Apixaban Tablet | — | 0/14 (0%) | 4/14 (28.6%) |
| Arm B: Apixaban Oral Solution | — | 0/13 (0%) | 2/13 (15.4%) |
| Event | Arm A: Apixaban Tablet | Arm B: Apixaban Oral Solution |
|---|---|---|
| HeadacheNervous system disorders | 2/14 | 1/13 |
| Throat irritationRespiratory, thoracic and mediastinal disorders | 0/14 | 1/13 |
| ConstipationGastrointestinal disorders | 1/14 | 0/13 |
| ToothacheGastrointestinal disorders | 1/14 | 0/13 |
| Vessel puncture site haematomaGeneral disorders | 1/14 | 0/13 |
| FatigueGeneral disorders | 1/14 | 0/13 |
| DyspepsiaGastrointestinal disorders | 1/14 | 0/13 |
| EructationGastrointestinal disorders | 1/14 | 0/13 |
All randomized participants
| Age, Continuous(years) | All Treatment Groups |
|---|---|
| Mean | 36 (28 to 44) |
| Sex: Female, Male(Participants) | All Treatment Groups |
|---|---|
| Female | 2 |
| Male | 12 |
The record gives a start of Feb 2010, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2016, 6 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apixaban